Genome&Company Logo

Genome&Company

Develops microbiome drugs and novel immune checkpoint inhibitors for immuno-oncology.

314130 | KO

Overview

Corporate Details

ISIN(s):
KR7314130006
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 창룡대로256번길 50 7층, 8층, 수원시

Description

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-09 00:00
주식등의대량보유상황보고서(일반)
Korean 103.6 KB
2025-05-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-05-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-08 00:00
주식등의대량보유상황보고서(약식)
Korean 70.8 KB
2025-05-07 00:00
주식등의대량보유상황보고서(약식)
Korean 67.6 KB
2025-04-30 00:00
주요사항보고서(타법인주식및출자증권양도결정)
Korean 21.5 KB
2025-04-28 00:00
증권발행결과(자율공시)
Korean 6.0 KB
2025-04-25 00:00
주요사항보고서(타법인주식및출자증권양수결정)
Korean 147.6 KB
2025-04-25 00:00
주요사항보고서(유상증자결정)
Korean 144.7 KB
2025-04-25 00:00
주요사항보고서(타법인주식및출자증권양수결정)
Korean 147.7 KB
2025-04-24 00:00
주요사항보고서(자본으로인정되는채무증권발행결정)
Korean 36.2 KB

Automate Your Workflow. Get a real-time feed of all Genome&Company filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genome&Company

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genome&Company via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.